BioDelivery Sciences International
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, BioDelivery Sciences International sits in the top decile of US sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count).
BioDelivery Sciences International: 17 sponsored US clinical trials, 1 recruiting.
BioDelivery Sciences International sponsors 17 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 16 completed. 9 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Painful Diabetic Neuropathy, with 1 trials.
Top-decile sponsor footprint
BioDelivery Sciences International ranks in the top decile of sponsors by registered trial count (#842 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
16 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
17 total, page 1 of 1
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
NCT03720613
Single Dose Crossover Study to Compare the Respiratory Drive After Administration of Belbuca, Oxycodone and Placebo.
NCT03996694
Efficacy, Tolerability, and Safety of DFN-15
NCT03009019
Efficacy, Tolerability, and Safety Study of DFN-15
NCT03006276
The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy
NCT02643251
A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy
NCT02355158
Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy
NCT02068027
Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film
NCT01871285
Long-term Open-Label Safety Study to Evaluate EN3409
NCT01755546
Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects
NCT01675167
Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects
NCT01633944
An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects
NCT01666119
Longterm Safety Study of BEMA Buprenorphine in Subjects With Chronic Pain
NCT01298765
Efficacy and Safety Study of Buprenorphine HCl Buccal Film in Subjects With Low Back Pain
NCT01256450
Study of Buprenorphine HCl Buccal Film in the Treatment of Dental Pain
NCT00941304
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
NCT00293020
Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
NCT00293033
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 6 |
| Phase 3 | 9 |
Therapeutic Areas
What is open in the BioDelivery Sciences International pipeline
1 recruiting of 17 indexed (6% open); 16 completed (94%).
Phase mix: 9 late (III/IV) vs 7 early (I/II) (balanced across stages).
Top condition: Painful Diabetic Neuropathy (1 trial), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
BioDelivery Sciences International: open-pipeline peers nationwide
Peers matched on 17 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
BioDelivery Sciences International sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 17 trials (± recruiting share)
- Achieve Life Sciences · 17 trials · 0% recruiting
- Chugai Pharmaceutical · 17 trials · 24% recruiting
- ConvaTec · 17 trials · 18% recruiting
- Durham VA Medical Center · 17 trials · 6% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Colgate Palmolive · 6% recruiting · 51 trials
- Essentia Health · 6% recruiting · 17 trials
- Madrigal Pharmaceuticals · 6% recruiting · 17 trials
- Southern Methodist University · 6% recruiting · 17 trials
Related
What to do with this BioDelivery Sciences International page
17 registered trials is a research-attention snapshot, not an endorsement of BioDelivery Sciences International or any single study.
- 1 of BioDelivery Sciences International's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Painful Diabetic Neuropathy is the condition BioDelivery Sciences International studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Painful Diabetic Neuropathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
BioDelivery Sciences International pipeline card: 17 registered trials from official public datasets.Report a data error.